Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

ClinicalTrials.gov ID: NCT04753034

Public ClinicalTrials.gov record NCT04753034. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of TER-101 Topical Ointment to Assess Efficacy and Safety in Subjects With Mild to Moderate Atopic

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.

Study identification

NCT ID
NCT04753034
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Teres Bio, Inc.
Industry
Enrollment
63 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 17, 2021
Primary completion
May 2, 2021
Completion
May 2, 2021
Last update posted
Jul 25, 2022

2021

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
12
Facility City State ZIP Site status
Teres Bio site 05 Scottsdale Arizona 85255
Teres Bio Site 04 Encinitas California 92024
Teres Bio Site 12 North Miami Beach Florida 33162
Teres Bio Site 10 Tampa Florida 33613
Teres Bio Site 02 Clarksville Indiana 47129
Teres Bio Site 01 Louisville Kentucky 40241
Teres Bio site 09 Saint Joseph Missouri 64506
Teres Bio Site 08 High Point North Carolina 27262
Teres Bio Site 11 Wilmington North Carolina 28405
Teres Bio Site 03 College Station Texas 77845
Teres Bio Site 06 Pflugerville Texas 78660
Teres Bio Site 07 San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04753034, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 25, 2022 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04753034 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →